CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »

Positive data reported for eptinezumab in Sunrise trial New insights on treatment holidays with erenumab Dual CGRP ligand mAb and gepant therapy reduces headache severity CGRP-mAb switching yields migraine day reduction Lower switching rates with atogepant than CGRP mAbs EMBRACE shows erenumab reduces migraine severity Older patients benefit from CGRP mAbs too DELIVER shows long term QoL benefits with eptinezumab

Aimovig (erenumab) available on NHS in England and Wales

22 March 2021 | News

The National Institute for Health and Care Excellence (NICE) has confirmed that erenumab can be prescribed for migraine prevention free of charge on the National Health Service (NHS) in England and Wales.

Physicians may consider erenumab 140 mg as an option for migraine prevention in adults who have four or more migraine days a month and have failed on at least three previous preventive drugs. Treatment should be stopped after 12 weeks if it does not reduce episodic migraine by at least 50% or chronic migraine by at least 30%.

Erenumab is already available on the NHS in Scotland.

Reference

National Institute for Health and Care Excellence. Erenumab for preventing migraine (TA682). March 2021

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2024 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |